COPT Defense Properties (NYSE:CDP) Releases FY 2026 Earnings Guidance

COPT Defense Properties (NYSE:CDP) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 2.730-2.790 for the period, compared to the consensus estimate of 2.780. The company issued revenue guidance of -. COPT Defense Properties also updated its Q2 2026 guidance to 0.680-0.700 EPS.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Citigroup lifted their price objective on COPT Defense Properties from $29.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, February 10th. Evercore reaffirmed an “outperform” rating and set a $38.00 price objective on shares of COPT Defense Properties in a report on Tuesday. Weiss Ratings raised COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, April 21st. Cantor Fitzgerald boosted their price target on COPT Defense Properties from $33.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, February 9th. Finally, Jefferies Financial Group boosted their price target on COPT Defense Properties from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.38.

COPT Defense Properties Price Performance

Shares of NYSE CDP traded down $0.56 during trading on Wednesday, reaching $31.53. The company had a trading volume of 42,894 shares, compared to its average volume of 1,153,932. COPT Defense Properties has a twelve month low of $25.21 and a twelve month high of $33.29. The stock has a market capitalization of $3.58 billion, a PE ratio of 22.85 and a beta of 0.86. The stock has a 50-day moving average price of $31.85 and a two-hundred day moving average price of $30.29. The company has a current ratio of 3.95, a quick ratio of 3.95 and a debt-to-equity ratio of 1.77.

COPT Defense Properties (NYSE:CDP) last released its quarterly earnings results on Monday, April 27th. The company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.34). The company had revenue of $200.64 million during the quarter, compared to analyst estimates of $185.41 million. COPT Defense Properties had a return on equity of 10.05% and a net margin of 20.10%.The business’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm earned $0.65 earnings per share. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. As a group, sell-side analysts predict that COPT Defense Properties will post 2.78 earnings per share for the current year.

COPT Defense Properties Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Tuesday, March 31st were paid a $0.32 dividend. The ex-dividend date was Tuesday, March 31st. This is an increase from COPT Defense Properties’s previous quarterly dividend of $0.31. This represents a $1.28 annualized dividend and a yield of 4.1%. COPT Defense Properties’s payout ratio is currently 94.81%.

Insider Buying and Selling

In related news, Director Philip L. Hawkins sold 5,536 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $32.71, for a total value of $181,082.56. Following the completion of the transaction, the director directly owned 15,188 shares in the company, valued at approximately $496,799.48. This represents a 26.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.66% of the company’s stock.

Hedge Funds Weigh In On COPT Defense Properties

Several institutional investors have recently added to or reduced their stakes in CDP. Royal Bank of Canada increased its stake in COPT Defense Properties by 12.1% in the first quarter. Royal Bank of Canada now owns 104,602 shares of the company’s stock valued at $2,853,000 after purchasing an additional 11,316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in COPT Defense Properties by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 67,030 shares of the company’s stock valued at $1,828,000 after acquiring an additional 2,931 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in COPT Defense Properties by 5.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 834,042 shares of the company’s stock valued at $22,744,000 after acquiring an additional 39,683 shares during the period. Jane Street Group LLC grew its position in COPT Defense Properties by 152.4% during the first quarter. Jane Street Group LLC now owns 214,122 shares of the company’s stock valued at $5,839,000 after acquiring an additional 129,303 shares during the period. Finally, Invesco Ltd. grew its position in COPT Defense Properties by 11.8% during the second quarter. Invesco Ltd. now owns 758,513 shares of the company’s stock valued at $20,920,000 after acquiring an additional 80,153 shares during the period.

COPT Defense Properties Company Profile

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.